Primary bone cancers (called osteosarcomas) affect more than 8,000 dogs, and possibly as many as 50,000 dogs per year in the United States. Although the risk for bone cancer is greatest in large and giant breeds, it is a health concern for many breeds. While osteosarcoma is treatable, only 30-40% of dogs that receive the standard of care survive one year or longer, and fewer than 20% are alive at two years. In addition, some dogs suffer significant treatment-related morbidity. Thus, better strategies to manage this cancer are needed.
To meet this need, investigators are developing tests that allow the detection of osteosarcoma at or near its origin. Early detection, in turn, will enable the deployment of strategic prevention in dogs at high risk. In this webinar, investigators will review their progress in developing a blood test for early detection of osteosarcoma as the initial step in their long-term strategy of early detection and targeted prevention for this deadly cancer.
This program has been submitted for RACE approval (but is not yet approved) for 1 hour of continuing education credit in jurisdictions which recognize RACE approval.
